So far, there has been no effective cure for osteoporotic cortical bone, the most significant change in long bone structure during aging and the main cause of bone fragility fractures, because its underlying molecular and cellular mechanisms remain largely unknown. We used 3-and 15-mo-old mice as well as 15-mo-old mice treated with vehicle and gefitinib to evaluate structural, cellular, and molecular changes in cortical bone. We found that the senescence of osteoprogenitors was increased, whereas the expression of phosphorylated epidermal growth factor receptor (EGFR) on the endosteal surface of cortical bone down-regulated in middle-aged 15-mo-old mice compared with young 3-mo-old mice. Further decreasing EGFR signaling by gefitinib treatment in middle-aged mice resulted in promoted senescence of osteoprogenitors and accelerated cortical bone degeneration. Moreover, inhibiting EGFR signaling suppressed the expression of enhancer of zeste homolog 2 (Ezh2), the repressor of cell senescence-inducer genes, through ERK1/2 pathway, thereby promoting senescence in osteoprogenitors. Down-regulated EGFR signaling plays a physiologically significant role during aging by reducing Ezh2 expression, leading to the senescence of osteoprogenitors and the decline in bone formation on the endosteal surface of cortical bone
Osteoporosis is described as a progressive systemic skeletal disease and is characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility and susceptibility to fracture (1) . Recent findings have emphasized the critical contributions of cortical bone in maintaining appendicular bone strength based on the evidence that cortical porosity is closely related to bone strength (2, 3) and that over 70% of age-related appendicular bone loss is in the cortical bone (3) (4) (5) . It is thought that the thinning and increased porosity in cortical bone during aging is due to an age-related remodeling imbalance between bone formation by osteoblasts and bone resorption by osteoclasts (6) . Recent studies have demonstrated that cortical degeneration resulted from delayed bone formation in intracortical and endosteal remodeling (7) (8) (9) . The underlying mechanism of delayed bone formation remains to be resolved. Cellular senescence, initially described as the proliferative arrest in cells grown in culture after a serial of divisions (10) , is widely suspected to be critical to the declined regenerative capacity of tissues with aging (11, 12) . Accompanying the growth arrest and dysfunction, the senescent cells can secret proinflammatory cytokines and chemokines, which develop a toxic microenvironment termed as senescence-associated secretory phenotype (SASP) (13) . Old mice have a dramatically decreased number of endosteal mesenchymal progenitors in the bone compared with young ones (12, 14) . Moreover, osteoprogenitors from the old mice exhibited elevated expression of SASP genes and increased osteoclast formation (12) . Therefore, with age advancing, accumulation of senescent cells and their SASP may alter the homeostasis and potentially promote age-related degenerative disease, including osteoporosis (15) . This is confirmed by the finding that suppressing the production of proinflammatory secretome of senescent cells using senolytic Janus kinase inhibitor has both antiresorptive and anabolic effects on bone, thus preventing age-related bone loss (12, 16) .
Epidermal growth factor (EGF) receptor (EGFR) signaling is critical to osteoprogenitor maintenance and new bone formation (17) . Inactivating it in mice by EGFR-specific inhibitors or knockdown of EGFR in osteoprogenitors and osteoblastic cells results in bone loss because of a decreased number of bone marrow mesenchymal progenitors (18) . Recently, it was reported that EGFR signaling protected cells from senescence and inhibited tissue aging (19) (20) (21) , and blocking EGFR signaling promoted cell senescence and tissue aging (21) . These studies strongly suggest that the EGFR signaling in osteoprogenitors might be important in prevention of cell senescence and regulation of cortical bone metabolism.
In the present study, we found down-regulated EGFR signaling in the osteoprogenitors at the endosteal surface of cortical bone in 15-mo-old mice. Furthermore, gefitinib, an EGFR-specific inhibitor, accelerated cortical bone degeneration in middle-aged mice. In addition, we found a fundamental function of the EGFR in osteoprogenitors that has previously been unknown: suppressing cell senescence at the endosteal surface and inhibiting the degeneration of cortical bone.
MATERIALS AND METHODS

Animals and treatments
All animal protocols were approved by the Institutional Animal Care and Use Committee at the Southern Medical University Nanfang Hospital before study, and all animal experiments were performed in accordance with Institutional Animal Care and Use Committee guidelines. Three-and fifteen-month-old C57BL/6J female mice were obtained from the Experimental Animal Center at Southern Medical University in Guangzhou, China. Mice were housed in facility under specific pathogen-free conditions at 25°C with a 12-h light/dark cycle and had access to food and water ad libitum. Fifteen-month-old female C57BL/6J mice were randomly assigned to treatments by oral gavage with gefitinib (100 mg/ kg/d; AZD1839; Selleckchem, Houston, TX, USA) or with vehicle (0.25% methylcellulose) for 1 mo. After euthanasia, their femurs and tibias were dissected for further analysis.
Micro-computed tomography analysis
For micro-computed tomography (mCT) analysis, femurs obtained from mice were dissected free of soft tissue, fixed overnight in 70% ethanol, and analyzed by a high-resolution mCT80 (Scanco Medical, Wangen-Brüttisellen, Switzerland). The scan was performed with an isotropic voxel size of 12 mm, set at a voltage of 55 kV P , a current of 145 mA, and an integration time of 400 ms, and averaged 2 times. We reconstructed and analyzed images using Image Processing Language v.5.15 software (Scanco Medical). The region of interest in cortical bone was defined as the one-third distal femur with a 900-mm-long section. The parameters, including bone mineral density (BMD), cortical area (Ct.Ar), cortical thickness (Ct.Th), cortical periosteal perimeter (Ct.Pe.Pm), and cortical endosteal perimeter (Ct.En.Pm) were calculated.
Immunofluorescence
For immunofluorescence analysis, the tibias were fixed in 4% paraformaldehyde for 24 h, decalcified in 10% EDTA (pH 7.4) for 4 wk, and embedded in paraffin. Six-micrometer-thick longitudinally oriented sections of bone were processed for immunofluorescence staining. The deparaffinized and rehydrated sections were treated with proteinase K for antigen retrieval and incubated with primary antibodies, such as rabbit anti-Ki67 (ab15580; Abcam, Cambridge, MA, USA), rabbit anti-Sp7/osterix (Osx; ab22552; Abcam), mouse anti-Sp7/Osx (sc-393060; Santa Cruz Biotechnology, Dallas, TX, USA), rabbit anti-phosphorylated (p)-EGFR (ET1606-44; HuaBio, Hangzhou, China), rabbit antip-ERK (4376S; Cell Signaling Technology, Danvers, MA, USA), mouse anti-inhibitor of cyclin-dependent kinase 4A (p16 INK4a ; ab54210; Abcam), and rabbit anti-enhancer of zeste homolog 2 (Ezh2; 5246S; Cell Signaling Technology), at 4°C overnight, followed by incubation with Alexa Fluor 594-conjugated goat anti-rabbit IgG (H+L; SA00006-4; Proteintech, Rosemont, IL, USA) and Alexa Fluor 488-conjugated goat anti-mouse IgG (H+L; SA00006-1; Proteintech) or with Alexa Fluor 594-conjugated goat anti-mouse IgG (H+L; SA00006-3; Proteintech) and Alexa Fluor 488 donkey anti-rabbit IgG (H+L; 1796375; Thermo Fisher Scientific, Waltham, MA, USA), respectively. Nuclei were counterstained with DAPI (E607303-0002; BBI Life Science, Shanghai, China). All sections were observed under a BX63 microscope (Olympus, Tokyo, Japan).
Bone endosteal mesenchymal progenitor culture
Osteoprogenitor cells from 3-to 15-mo-old C57BL/6 mice were obtained following the protocol as previously described in Siclari et al. (14) . Briefly, after euthanasia, the bilateral femurs and tibias were dissected free of soft tissues. After both ends of long bones were removed, the bone marrow was flushed out with a-MEM and discarded. To remove the perioseal progenitors, the flushed long bones were then digested with proteinase solution (2 mg/ml collagenase A and 2.5 mg/ml trypsin in PBS). Next, the bones were longitudinally cut into halves and then digested in fresh protease solution for 1 h. The cells in supernatant were collected, washed twice with culture medium, passed through cell strainer, and then cultured in growth medium (a-MEM containing 20% fetal bovine serum, 55 mM b-mercaptoethanol, 2 mM glutamine, 100 IU ml penicillin, and 100 mg/ml streptomycin).
For colony-forming unit-fibroblast (CFU-F) assay, primary endosteal osteoprogenitors at passage 0 were isolated and seeded at 1 3 10 6 per well in a 6-well plate in growth medium. On d 9, when cell colonies formed, cells were washed twice with PBS, fixed with 4% paraformaldehyde, and then stained with 3% crystal violet in methanol. The numbers and diameters of CFU-F were quantified, and only the colonies composed of more than 50 cells or those larger than 1 mm in diameter were counted.
Cell treatments and senescence-associated b-galactosidase staining
For gene expression analysis, primary endosteal osteoprogenitors from 3-mo-old C57BL/6 mice at passages 1 to 3 were seeded at 5 3 10 5 per well in a 6-well plate. Cells at 70-80% confluency were pretreated with 10 mM U0126 (Selleckchem) or 10 mM tazemetostat (Selleckchem) for 30 min before addition of 50 ng/ ml EGF (Peprotech, Rocky Hill, NJ, USA). On d 3, total RNA and protein were harvested, and expression of the genes was detected using real-time quantitative PCR and Western blotting, respectively.
For senescence-associated b-galactosidase (SA-b-Gal) staining, primary endosteal osteoprogenitors from 3-mo-old C57BL/6 mice at passages 1 to 3 were seeded at 2 3 10 5 per well in a 12-well plate. Cells at 60-70% confluency were pretreated with 10 mM gefitinib, 10 mM U0126, or 10 mM tazemetostat for 30 min before addition of EGF. On d 3, senescent cells were detected by a SA-b-Gal Staining Kit (9860; Cell Signaling Technology) according to the manufacturer's instructions.
Western blot analysis
Cells or tissues were homogenized in RIPA buffer (FD009; FdBio Science, Shenzhen, China) with protease inhibitors (KGP250; KeyGen BioTech, Jiangning, China). Total protein was collected by centrifugation, and protein concentrations were determined by PierceTM BCA Protein Assay Kit (SE248347; Thermo Fisher Scientific). Thirty micrograms of total protein from each sample was separated by SDS-PAGE and transferred to PVDF membranes. The membranes were incubated with the primary antibodies, such as rabbit anti-EGFR (ET1603-37; HuaBio), rabbit anti-p-EGFR (ET1606-44; HuaBio), rabbit anti-glyceraldehyde 3phosphate dehydrogenase (GAPDH; ET1601-4; HuaBio), and rabbit anti-EZH2 (5246S; Cell Signaling Technology), at 4°C overnight and subsequently with the secondary antibody conjugated with horseradish peroxidase at room temperature for 1 h. Signals were developed by ECL (Mil-liporeSigma, Burlington, MA, USA) and visualized by Tanon chemiluminescence apparatus. Protein densitometry was quantified by ImageJ software (National Institutes of Health, Bethesda, MD, USA).
RNA isolation and real-time quantitative PCR analysis
Total RNA was isolated from cells using RNAiso Plus (Takara, Kyoto, Japan). The 53 PrimeScript RT Master Mix (Takara) was used to reverse transcribe mRNA into cDNA. Following this, real-time quantitative PCR was performed using TB Green Premix Ex Taq II (Takara). The primer sequence for the genes used in this study were as follows: GAPDH (forward, 59-TGTCGTGGAGTC-TACTGGTG-39; reverse, 59-GCATTGCTGACAATCTTGAG-39), p16 INK4a (forward, 59-GAAAGAGTTCGGGGCGTTG-39; reverse, 59-GAGAGCCATCTGGAGCAGCAT-39), and p53 (forward, 59-ATCGCCTTCGACATCATCGC-39; reverse, 59-CCCCATGCGTA-CTCCATGAG-39). The relative expression of each target gene was calculated using 2 2DDCt method with GAPDH for normalization.
Statistical analysis
All results were expressed as means 6 SE. An unpaired Student's t test was used to evaluate the statistical difference between 3and 15-mo-old groups or between control and gefitinib-treated groups. In cases of multiple groups, differences were analyzed with 1-way ANOVA with Bonferroni posttest. For analysis using primary osteoprogenitors, experiments were repeated independently at least 3 times. Values of P , 0.05 were considered statistically significant.
RESULTS
Osteoprogenitors senescence occurs in the endosteum of cortical bone
To determine whether cortical bone might change with age, femora were harvested from young 3-mo-old mice and middle-aged 15-mo-old mice. The microstructure of femoral cortical bone was measured by mCT. We found the trabecular-like structure at the inner part of cortical bone of femoral metaphysis ( Fig. 1A) and that the thickness of cortical bone in 15-mo-old mice was much thinner than that in 3-mo-old ones ( Fig. 1A, C) . Quantitative analysis showed that the cortical BMD, Ct.Th, and Ct.Ar decreased significantly by about 5.96% (P , 0.05), 25.24% (P , 0.01), and 19.26% (P , 0.01) ( Fig. 1B-D) , respectively, in 15mo-old mice compared with 3-mo-old mice. In addition, the Ct.Pe.Pm and Ct.En.Pm in 15-mo-old mice increased significantly by 5.48% (P , 0.05) and 13.07% (P , 0.01), respectively, compared with 3-mo-old mice (Fig. 1E, F) . The above results indicated significant degeneration of cortical bone in the 15-mo-old mice.
We next isolated osteoprogenitors from the endosteal bone surfaces of femoral cortical bone for CFU-F assay to measure the number and proliferative capacity of endosteal osteoprogenitors from these mice. As shown in Fig.  1G -I, the colony number and diameter of the cells from 15mo-old mice significantly decreased compared with that in 3-mo-old ones. We thus reasoned that the capacity of cells in middle-aged mice might be much less proliferative. Indeed, there were significantly fewer Osx + Ki67 + cells in the endosteum of cortical bone in 15-mo-old mice compared with 3-mo-old ones (double-immunofluorescence staining detecting Osx, an osteoprogenitor marker, and Ki67, a cell proliferation marker) ( Fig. 1J, K) . As age-related tissue dysfunction has been linked to cellular senescence (22) , we examined whether the decreased proliferation might be associated with cellular senescence. Doubleimmunofluorescence staining detecting Osx and the senescence biomarker p16 INK4a were tested. The number and fluorescent intensity of Osx + p16 INK4a+ were significantly increased in the 15-mo-old mice ( Fig. 1L-N) . Taken together, these data suggest that senescence of endosteal osteoprogenitors might be linked to decreased bone remodeling and thinner cortical bone.
EGFR signaling in osteoprogenitors inhibits cell senescence
As EGFR is highly expressed in bone mesenchymal stromal cells (BMSCs) or osteoprogenitor cells and its ligand EGF is a potent proliferator of BMSCs and osteoprogenitor cells (23, 24) , we next tested whether EGFR signaling might be altered in the cortical bone during aging. Western blot analysis showed that the protein levels of p-EGFR decreased dramatically in the cortical bone of 15-mo-old mice ( Fig. 2A, B) . Consistently, double-immunofluorescence staining showed significantly decreased number and fluorescent intensity of Osx + p-EGFR + cells (Fig. 2C-E) . To further establish the relationship between EGFR signaling and cell senescence in osteoprogenitors, we then detected the mRNA expression of p16 INK4a and p53, the senescence markers, in the cortical bone of 3-and 15-mo-old mice and found significantly up-regulated expression of the two genes (Fig. 2F) . In vitro, we treated endosteal osteoprogenitors with EGF in the presence or absence of gefitinib, an EGFR inhibitor. Results showed that the EGF treatments suppressed the mRNA expression of p16 INK4a and p53, whereas gefitinib significantly blocked the effect of EGF treatment (Fig. 2G) . These data indicate that downregulated EGFR signaling in endosteal osteoprgenitors might induce cell senescence.
We further asked whether inhibition of EGFR signaling might promote the senescence of osteoprogenitors in endosteum and accelerate the cortical bone degeneration. Fifteen-month-old mice were treated with vehicle (control) or gefitinib, an EGFR-signaling inhibitor for 1 mo. Results showed that the Ct.Th and Ct.Ar in the gefitinib-treated mice decreased by 11.23% (P , 0.05) and 14.56% (P , 0.05), respectively, compared with the vehicle-treated mice (Fig.  3A-D) . There was with no significant alteration in the Ct.Pe.Pm, whereas the Ct.En. Pm was significantly enlarged ( Fig. 3E, F) . Immunofluorescence staining of the endosteum of cortical bone showed an elevated number and fluorescent intensity of Osx + p16 INK4a+ cells (Fig. 3G-I ), suggesting that suppression of EGFR signaling in osteoprogenitors might have promoted senescence of cells. Moreover, we observed decreased senescence of endosteal osteoprogenitor cells by EGF treatment and increased senescence by gefitinib treatment (Fig. 3J, K) . These observations indicate that down-regulation of EGFR signaling during aging might induce cortical bone degeneration by inducing the senescence of osteoprogenitors.
Because Ras-Raf-MAPK is the major EGFR downstream signaling pathway (25), we performed immunofluorescence to detect the phosphorylation of ERK1/2 (p-ERK). As shown in Fig. 4A -C, 15-mo-old mice had a significantly decreased number and fluorescent intensity of Osx + p-ERK + cells. To confirm this, we cultured endosteal osteoprogenitor cells and treated them with EGF in the presence or absence of U0126, an inhibitor of ERK pathway. Quantitative real-time PCR results showed that the EGF treatment suppressed the mRNA expression of senescence-related genes and U0126 blocked the effect of EGF treatment (Fig. 4D) . Consistent with this, SA-b-Gal staining demonstrated that U0126 blocked the inhibitory effect of EGF on cell senescence (Fig. 4E, F) . These results indicate that EGFR signaling might regulate the senescence of osteoprogenitors through the ERK pathway.
EGFR/ERK signaling inhibits cellular senescence by Ezh2
Ezh2, a polycomb histone methyltransferase, is one of the important factors regulating chromatin remodeling and cell senescence of BMSCs and osteoprogenitor cells (26, 27) . Our recent work found that specific knockout of Ezh2 caused cell senescence in mice and decreased the number of BMSCs and osteoprogenitor cells, leading to osteoporosis (26) . We went on to address whether the expression level of Ezh2 might change with aging. Western blotting results showed that the expression of Ezh2 decreased significantly in the bone of 15-mo-old mice compared with 3-mo-old mice (Fig. 5A, B) . To further investigate whether the expression of Ezh2 might be down-regulated in osteoprogenitors, we performed double-immunofluorescence staining. Results showed that the number and fluorescent intensity of Osx + Ezh2 + cells decreased significantly in the endosteum of cortical bone in 15-mo-old mice compared with that in 3-mo-old mice (Fig. 5C-E) .
To test whether the down-regulated expression of Ezh2 might contribute to the decreased EGFR signaling in middle-aged mice, we further reduced EGFR signaling by gefitinib treatment in the 15-mo-old mice. Results showed that reducing EGFR signaling further down-regulated Ezh2 expression in bone, as shown by Western blotting results in Fig. 6A, B . Consistently, immunofluorescence staining results showed that the number and fluorescent intensity of Osx + Ezh2 + cells were significantly decreased by gefitinib treatment (Fig. 6C-E) . We next evaluated whether Ezh2 might mediate the role of EGFR signaling in regulating the viability of cells. In primary endosteal osteoprogenitors, EPZ-6438 (EPZ), an inhibitor of Ezh2, significantly blocked the effect of EGF on the mRNA expression of p16 INK4a (Fig. 6F) . Consistent with this, SAb-Gal staining also showed that EPZ significantly blocked the effect of EGF on cell viability and promoted the senescence of the cells (Fig. 6G, H) . In addition, we found that EGF stimulated the expression Ezh2 and U0126 blocked this effect (Fig. 6I, J) . These data indicate that Ezh2 may mediate the effect of EGFR/ERK pathway on cell viability.
DISCUSSION
Both women and men show age-dependent decline in cortical bone thickness and strength, which increase the risk of fragility fracture (28) . However, the underlying molecular mechanism remains poorly understood. Here, we have elucidated the mechanisms by which down-regulated EGFR signaling in endosteal osteoprogenitors may be associated with cortical bone degeneration during aging. We found that EGFR/ERK/ Ezh2 signaling in endosteal osteoprogenitors decreased with aging, and it was associated with senescence of osteoprogenitors and cortical bone degeneration, which could be further accelerated by inhibiting EGFR/ERK/ Ezh2 signaling. Additionally, activating EGFR signaling by EGF could block cell senescence. We believe these are the first attempts to identify the mechanisms by which degeneration of cortical bone occurs. Consequently, targeting the down-regulated EGFR/ERK/Ezh2 signaling may provide a new therapeutic prevention of cortical bone degeneration.
In aging humans, degeneration of cortical bone is characterized by increased cortical porosity and reduced Ct.Th (29) . The age-related cortical porosity is mainly associated with an enlarged size of canals (29, 30) . It was reported that unbalanced intracortical remodeling with delayed or absent initiation of bone formation on existing pores might lead to enlarged canals in human cortical bone (30) . However, no osteon structure was found in mouse cortical bone, which rarely underwent intracortical remodeling (31) . A recent study reported that age-dependent cortical bone loss was associated with increased DNA damage, cellular senescence of osteocyte, and unbalanced endosteal remodeling because increased osteoclasts and decreased osteoblasts led to decreased cortical bone thickness (9) . Our present work further demonstrated that decreased bone formation in endosteum might be attributed to the increased senescence of osteoprogenitors. Together, these data suggest that age-related dysfunction of osteocytes and unbalance endosteal remodeling may be responsible for the cortical bone thinning.
With advancing age, the dysregulation of bone remodeling occurs in all skeletal bones, and the greater bone loss occurs near the endocortical wall, leading to cortical wall thinning (8) . Cortical thinning of long bone starts at ;5.5 mo of age and progresses with aging in C57BL/6J male mice (32) . Recent evidence showed that endocortical resorption exceeded formation, whereas periosteal resorption and formation were balanced, resulting in cortical thinning and a net bone loss in 26-wk-old (adult) and 78-wk-old (elderly) mice (33) . Consistent with the above literature, our study showed that middle-aged mice had thinner cortical bone and a shorter endosteal perimeter, indicating dysregulation of remodeling in the endosteum of cortical bone. Furthermore, our study demonstrated enhanced senescence of osteoprogenitors at the endocortical surface in middle-aged mice, suggesting that diminished endocortical bone formation in the elderly might be likely caused by senescence of osteoprogenitors. This is in line with a previous study showing that synolytics targeting senescence might prevent age-related cortical bone loss (16) . EGFR signaling has been reported to be important for cortical bone metabolism. Deficiency of EGFR signaling by gefitinib treatment induces thinning of cortical bone in 7mo-old mice (18) . Consistent with this, our present study found that EGFR signaling in endosteal osteoprogenitors was down-regulated with aging and that suppressing EGFR signaling accelerated the age-related degeneration in mouse cortical bone. It was reported that activation of EGFR increased the number of osteoprogenitors cells by promoting cell proliferation and suppressing either serum depletion-induced or TNF-a-induced apoptosis (17) , and blocking EGFR was capable of altering the balance between proliferating vs. apoptotic and senescent cells (34) . In agreement, our in vivo and in vitro experiments demonstrated that EGFR signaling was essential for viability of endosteal osteoprogenitors. Furthermore, we demonstrated that inhibition of ERK/MAPK pathway could promote the senescence of endosteal osteoprogenitors and block the survival and proliferation ability of osteoprogenitors induced by EGF treatment. This is consistent with a recent report that EGFR signaling promotes proliferation of hair follicle-derived mesenchymal stem cells through ERK1/2 and suppresses the expression of the p16 INK4a (35) . Therefore, advancing age is associated with a decrease in EGFR/ERK signaling whereby endosteal osteoprogenitors undergo senescence, leading to decreased endosteal bone formation and cortical bone degeneration.
Our recent work demonstrated that senescence of osteoprogenitor was epigenetically controlled by Ezh2, and knockout of Ezh2 resulted in cellular senescence, depleted progenitor cells, and osteoporosis (26) . Interestingly, our present work showed the age-related decline in the expression of Ezh2 in osteoprogenitors. This is consistent with a recent report that hematopoietic progenitor cell senescence is associated with altered expression profiles of genes, including decreased expression of Ezh2 in older mice (36) . More importantly, our study has demonstrated that Ezh2 expression is regulated by EGFR/ERK signaling in osteoprogenitors. Our data extend the current understanding that the down-regulated level of EGFR/ERK/ Ezh2 signaling may contribute to osteoprogenitor senescence and age-related degeneration of cortical bone.
This study has 2 limitations. First, the parameters assessing the porosity of mouse cortical bone are lacking because of the restricted resolution of mCT performed. The ultrastructure of mouse cortical bone shows extensive canal spaces in the diaphysis cortical bone (31) . Future work is needed to quantify the age-related porosity in cortical bone and to determine whether it is associated with down-regulated EGFR signaling. Second, we did not specifically knock down the EGFR signaling in endosteal osteoprogenitors to verify the role of osteoprogentor-specific EGFR signaling in endosteal cortical bone remodeling. It will be important in future studies to assess the functional role of osteoprogenitor-specific EGFR signaling in controlling endosteal cortical bone remodeling and degeneration.
In summary, our study demonstrates that EGFR signaling in osteoprogenitors may be one of the critical mechanisms that restrain the senescence of cells on endocortical surfaces in an age-dependent manner. Down-regulation of EGFR/ERK signaling with aging leads to reduced expression of Ezh2, thereby inducing senescence of cells and degeneration of cortical bone. This study establishes the essential role of EGFR signaling in cortical bone degeneration during aging.
